Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Ben Creelan's publication output changed over time?
ScholarIQpublication output · 2015–2025
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2025.
1
2
2
2
2
1
1
2015201720182019202020212025
What are the most-cited papers on Ben Creelan?
ScholarIQmost cited works
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
New England Journal of Medicine. 20172,585 CitationsOPEN ACCESS
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok
S25671836. 20181,186 CitationsOPEN ACCESS
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
Matthew B. Schabath, E A Welsh, William J. Fulp, Lieping Chen, Jamie K. Teer, Zachary Thompson, Brienne E. Engel, Min Xie, Anders Berglund, Ben Creelan, S. Antonia, Jhanelle E. Gray, Steven A. Eschrich, D-T Chen, W. Douglas Cress, Eric B. Haura, Amer A. Beg
S128439998. 2015452 Citations
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Ben Creelan, Chao Wang, Jamie K. Teer, Eric M. Toloza, Jiqiang Yao, Sungjune Kim, Ana Marie Landin, John E. Mullinax, James J. Saller, Andreas Saltos, David Noyes, Leighann B. Montoya, Wesley Curry, Shari Pilon‐Thomas, Alberto Chiappori, Tawee Tanvetyanon, Frederic J. Kaye, Zachary Thompson, Sean Yoder, Bin Fang, John M. Koomen, Amod A. Sarnaik, Dung‐Tsa Chen, José R. Conejo-García, Eric B. Haura, Scott Antonia
Nature Medicine. 2021428 CitationsOPEN ACCESS
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
David Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben Creelan, Lawrence H. Einhorn, Justin Baker, Samer S. Kasbari, Petros Nikolinakos, Sunil Babu, Félix Couture, Natasha B. Leighl, Craig H. Reynolds, George R. Blumenschein, Vijay Gunuganti, Ang Li, Nivedita Aanur, David R. Spigel
Journal of Clinical Oncology. 2020241 CitationsOPEN ACCESS
Related on ScholarIQ
Moffitt Cancer Center
Institution
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Paper
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Paper
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
Paper
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Paper
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
Paper